Drug intelligence / Profile preview

BMS-905

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-905 is a potent, selective, orally active dual antagonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). Developed by Bristol Myers Squibb, it is a structural analog of afimetoran (BMS-986256). BMS-905 has demonstrated robust, dose-dependent efficacy in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis, where it suppresses kidney inflammation, autoantibodies, and interferon-response genes by blocking TLR7/8-mediated NFκB and IRF signaling.

Other names: 2-(2,6-dimethylpyridin-4-yl)-3-isopropyl-5-(piperidin-4-yl)-1H-indole

Targets

TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on BMS-905.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-905.